[{"id":"9bd42bb7-1fd2-4126-995e-0c74a47e0e47","acronym":"","url":"https://clinicaltrials.gov/study/NCT05665075","created_at":"2022-12-27T15:59:02.163Z","updated_at":"2024-07-02T16:35:58.332Z","phase":"Phase 1","brief_title":"Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia","source_id_and_acronym":"NCT05665075","lead_sponsor":"Zhejiang University","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • fludarabine IV • QN-023a"],"overall_status":"Recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 12/24/2022","start_date":" 12/24/2022","primary_txt":" Primary completion: 12/24/2023","primary_completion_date":" 12/24/2023","study_txt":" Completion: 12/24/2025","study_completion_date":" 12/24/2025","last_update_posted":"2023-01-02"},{"id":"07ab1569-8076-4047-9873-382e6164c635","acronym":"","url":"https://clinicaltrials.gov/study/NCT05601466","created_at":"2022-11-03T04:55:58.967Z","updated_at":"2024-07-02T16:36:00.901Z","phase":"Phase 1","brief_title":"Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia","source_id_and_acronym":"NCT05601466","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • fludarabine IV • QN-023a"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 10/28/2022","start_date":" 10/28/2022","primary_txt":" Primary completion: 10/21/2025","primary_completion_date":" 10/21/2025","study_txt":" Completion: 10/21/2025","study_completion_date":" 10/21/2025","last_update_posted":"2022-11-07"}]